SSA
NTLA icon

Schonfeld Strategic Advisors’s Intellia Therapeutics NTLA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,600
Closed -$3.01M – 2367
2021
Q2 		$3.01M Buy
+18,600
New +$1.45M 0.03% 590

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Schonfeld Strategic Advisors's NTLA Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 59,592 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #1475 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in NTLA as recently as Q4 2025.

Schonfeld Strategic Advisors first reported a position in NTLA in Q2 2016 and has held it in 18 quarters since. The position peaked at $4.17M in Q2 2024. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Schonfeld Strategic Advisors held 59,592 shares of Intellia Therapeutics worth $1.01M as of Q2 2026.
  • Intellia Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Intellia Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #1475 holding.
  • Schonfeld Strategic Advisors first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 18 quarters since.
  • Schonfeld Strategic Advisors's Intellia Therapeutics position peaked at $4.17M in Q2 2024.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.